Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Centessa Pharmaceuticals plc
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| HUSSAIN IQBAL J (General Counsel) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 7,520 shares
@ $6.47, valued at
$48.7k
|
|
| 10/03/2023 |
4
| GRAINGER DAVID J (Chief Innovation Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 4,700 shares
@ $6.47, valued at
$30.4k
|
|
| 10/03/2023 |
4
| Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 11,742 shares
@ $6.47, valued at
$76k
|
|
| 10/03/2023 |
4
| SAHA SAURABH (CEO) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 36,263 shares
@ $6.47, valued at
$234.6k
|
|
| 10/03/2023 |
4
| CHAO DAVID M (Chief Administrative Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 10,419 shares
@ $6.47, valued at
$67.4k
|
|
| 10/03/2023 |
4
| Bush Tia L (Chief Quality Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 6,419 shares
@ $6.47, valued at
$41.5k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 11,742 shares
@ $5.9001, valued at
$69.3k
|
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
4
| YVER ANTOINE (EVP & Chairman of Development) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Sold 6,500 shares
@ $4.4537, valued at
$28.9k
|
|
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/26/2023 |
4
| Bush Tia L (Chief Quality Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Sold 5,000 shares
@ $4.485, valued at
$22.4k
Sold 3,000 shares
@ $4.4801, valued at
$13.4k
|
|
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/15/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/15/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/04/2023 |
4
| CHAO DAVID M (Chief Administrative Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 6,969 shares
@ $3.9, valued at
$27.2k
|
|
| 04/04/2023 |
4
| Weinhoff Gregory M (CFO) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 8,292 shares
@ $3.9, valued at
$32.3k
|
|
| 04/04/2023 |
4
| Templeman Thomas (Chief Technology Officer) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 4,103 shares
@ $3.9, valued at
$16k
|
|
| 04/04/2023 |
4
| SAHA SAURABH (CEO) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 22,013 shares
@ $3.9, valued at
$85.9k
|
|
| 04/04/2023 |
4
| HUSSAIN IQBAL J (General Counsel) has filed a Form 4 on Centessa Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 7,080 shares
@ $3.9, valued at
$27.6k
|
|
|
|
|